Brexucabtagene autoleucel consolidation in adult B-cell acute lymphoblastic leukemia: real-world efficacy and toxicity

Blood Immunology & Cellular Therapy 2026 Open access

Read full text
Authors: Nitin Jain, Niranjan Khaire, Nicholas Short, Shilpa Paul, Alexandra Lovell, Jayastu Senapati, Hannah Goulart, Gautam Borthakur, Tapan Kadia, Koichi Takahashi, Naveen Pemmaraju, Naval Daver
+17 more Ghayas Issa, Musa Yilmaz, Fadi G. Haddad, Jen Wei Ying, Rabiul Islam, Rebecca E. Garris, Sa Wang, Beenu Thakral, Partow Kebriaei, Bouthaina Dabaja, Elizabeth Shpall, Sattva Neelapu, William Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Elias Jabbour
DOI: 10.1016/j.bict.2026.100059
Cited by: 1
References: 12

Abstract

Brexucabtagene autoleucel (brexu-cel), a CD19 chimeric antigen receptor (CAR) T cell is approved for patients with relapsed/refractory B-cell acute lymphoblastic leukemia. In the pivotal ZUMA-3 trial, patients were required to have >5% marrow blasts. We aimed to evaluate efficacy/toxicity with brexu-cel in a real-world setting with marrow blasts of

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research CAR-T cell therapy research Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Blood Immunology & Cellular Therapy
Publisher
Elsevier BV
Volume
2
Issue
2
Pages
100059–100059
Publication date
5 May 2026
Language
EN